Novel, adaptive designs are seen by many drug developers as highly attractive as they seemingly offer more for less: more in terms of considerable flexibility in…
FDA reviews the learning from 22 case studies. Despite what are often reported as promising phase II data, the subsequent failure rate in phase III remains…
KJC statistics is pleased to announce a working collaboration with Ms Claire Watkins, MSc, of ClaroStat Consulting. Claire has over 15 years experience as a professional…
KJC Statistics will be attending Kidney Week 2016 in Chicago. Kidney Week, which takes place from the 15th – 20th November, is the world’s premier nephrology…
